Fully Automated Digital Immunoassay for Neurofilament Light Chain in Blood

The Simoa Nf-L assay pioneered the measurement of neurofilament light chain in plasma and serum and has since been validated by hundreds of publications across numerous disease areas including Multiple Sclerosis (MS), Alzheimer’s Disease (AD), Traumatic Brain Injury (TBI), and Amyotrophic lateral sclerosis (ALS).

With the support of large normative reference range databases, the Simoa Nf-L assay is suitable for clinical implementation as a laboratory-developed test. Download the whitepaper to learn more about the clinical implementation and use of the Simoa Nf-L test offered by Quanterix as a laboratory-developed test. Download the whitepaper to learn more.